摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-ethyl-pyrido[2,3-d]pyrimidin-7-yl}-urea | 352328-39-3

中文名称
——
中文别名
——
英文名称
1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-ethyl-pyrido[2,3-d]pyrimidin-7-yl}-urea
英文别名
1-tert-butyl-3-[2-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]anilino]-6-ethylpyrido[2,3-d]pyrimidin-7-yl]urea
1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-ethyl-pyrido[2,3-d]pyrimidin-7-yl}-urea化学式
CAS
352328-39-3
化学式
C26H36N8O
mdl
——
分子量
476.625
InChiKey
BDWLNZXAMQPJNX-CALCHBBNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    35
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    107
  • 氢给体数:
    4
  • 氢受体数:
    7

文献信息

  • Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
    申请人:——
    公开号:US20030073668A1
    公开(公告)日:2003-04-17
    Disclosed are compounds of the formula (I) wherein: R 2 , R 7 , RI 3 , R 14 and R 15 are independently hydrogen, or (un)substituted lower alkyl, (un)substitued lower alkenyl, (un)substituted lower alkynyl, or (un)substituted —(CH 2 ) n R 12 ; R 5 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , or —OR 9 ; R 6 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —Co 2 R 9 , —COR 9 , —CONR 9 R 10 , —NR 9 COR 10 , (un)substiuted lower alkenyl, or (un)substituted lower alkynyl; R 8 is —CO 2 R 13 , —COR 13 , —CONR 13 R 14 , —CSNR 13 R 14 , —C(NR 13 )NR 14 R 15 , —SO 3 R 13 , —SO 2 R 13 , —SO 2 NR 13 R 14 , —PO 3 R 13 R 14 , —POR 13 R 14 , —PO(NR 13 R 14 ) 2 ; R 9 and R 10 are independently hydrogen or (un)substituted lower alkyl; R 11 is a heteroaryl or a heterocyclic group; R 12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group; and n is 0,1,2, or 3. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.
    披露了公式(I)的化合物,其中:R2、R7、R13、R14和R15独立为,或(未)取代的低烷基,(未)取代的低基,(未)取代的低炔基,或(未)取代的—(CH2)nR12;R5为卤素,基,硝基,—R9,—NR9R10,或—OR9;R6为卤素,基,硝基,—R9,—NR9R10,—OR9,—Co2R9,—COR9,—CONR9R10,—NR9COR10,(未)取代的低基,或(未)取代的低炔基;R8为—CO2R13,—COR13,—CONR13R14,—CSNR13R14,—C(NR13)NR14R15,—SO3R13,—SO2R13,—SO2NR13R14,—PO3R13R14,—POR13R14,—PO(NR13R14)2;R9和R10独立为或(未)取代的低烷基;R11为杂芳基或杂环基团;R12为环烷基,杂环,芳基,或杂芳基团;n为0,1,2,或3。这些化合物及其药物组合物可用于治疗细胞增殖障碍,如癌症和再狭窄。这些化合物是cdks和生长因子介导激酶的强效抑制剂
  • US7053070B2
    申请人:——
    公开号:US7053070B2
    公开(公告)日:2006-05-30
查看更多